Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 9:37 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2473–2496 of 4,226 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Injectable Placebo Clear all

Conditions: Healthy
Interventions: Placebo, RSV preF Protein 50 mcg, RSV preF Protein 150 mcg, Ad26.RSV.preF 1*10^11 vp, Mixture of Ad26.RSV.preF 5*10^10 vp Plus RSV preF Protein 50 mcg, Mixture of Ad26.RSV.preF 5*10^10 vp Plus RSV preF Protein 150 mcg, Mixture of Ad26.RSV.preF 1*10^11 vp Plus RSV preF Protein 50 mcg, Mixture of Ad26.RSV.preF 1*10^11 vp Plus RSV preF Protein 150 mcg, Selected Regimen; Biological
Lead sponsor: Janssen Vaccines & Prevention B.V.; Industry
Eligibility: 60 Years and older
Enrollment: 669 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2022
U.S. locations: 6
States / cities: Huntsville, Alabama • San Diego, California • Melbourne, Florida + 3 more

Conditions: Type 1 Diabetes Mellitus With Hypoglycemia
Interventions: Placebo, ZT-01, 7 mg, ZT-01, 15 mg, ZT-01, 22 mg; Drug
Lead sponsor: Zucara Therapeutics Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 186 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 38
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Escondido, California + 34 more

Conditions: Amyotrophic Lateral Sclerosis (ALS)
Interventions: NurOwn® (MSC-NTF cells), Placebo, Bone Marrow aspiration; Biological · Other
Lead sponsor: Brainstorm-Cell Therapeutics; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 196 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 6
States / cities: Irvine, California • Los Angeles, California • San Francisco, California + 3 more

Conditions: Inflammation, Pain, Cataract
Interventions: XG-102, Placebo; Drug
Lead sponsor: Xigen SA; Industry
Eligibility: 18 Years and older
Enrollment: 309 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Andover, Massachusetts

Conditions: Gastroparesis
Interventions: Botulinum toxin A, Placebo; Drug
Lead sponsor: Temple University; Other
Eligibility: 18 Years to 70 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2008
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Asthma
Interventions: Tralokinumab, Placebo; Biological · Other
Lead sponsor: AstraZeneca; Industry
Eligibility: 12 Years to 75 Years
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 15
States / cities: New Haven, Connecticut • Clearwater, Florida • St Louis, Missouri + 12 more

Conditions: Type 2 Diabetes Mellitus (T2DM)
Interventions: PE0139 Injection, Placebo; Drug
Lead sponsor: PhaseBio Pharmaceuticals Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 3
States / cities: Anniston, Alabama • Hialeah, Florida • Renton, Washington

Conditions: Schizophrenia
Interventions: Ralmitaront, Radiolabeled PET tracer [18F]-DOPA, Placebo; Drug · Other
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 50 Years · Male only
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 4
States / cities: Glendale, California • Torrance, California • Gaithersburg, Maryland + 1 more

Conditions: Type 2 Diabetes Mellitus (T2DM)
Interventions: ALN-KHK, Placebo; Drug
Lead sponsor: Alnylam Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 49 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2025
U.S. locations: 11
States / cities: Phoenix, Arizona • Vista, California • Lake Worth, Florida + 8 more

Conditions: Pleural Disease, Postoperative Pain
Interventions: Bupivacaine injection, Placebo, Monitored Anesthesia Care; Drug · Other
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: New York, New York

Conditions: Intracranial Embolism, Cerebral Thromboembolism, Carotid Stenosis
Interventions: ARC1779 Injection, Placebo (normal saline); Drug
Lead sponsor: Archemix Corp.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 2
States / cities: Hackensack, New Jersey • Houston, Texas

Conditions: Psoriatic Arthritis
Interventions: Placebo, Ixekizumab 80 mg Q4W, Ixekizumab 80 mg Q2W; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 363 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 59
States / cities: Birmingham, Alabama • Glendale, Arizona • Mesa, Arizona + 50 more

Conditions: Respiratory Syncytial Virus
Interventions: Placebo, mRNA-1345, Fluzone HD; Biological
Lead sponsor: ModernaTX, Inc.; Industry
Eligibility: 65 Years and older
Enrollment: 1,900 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 34
States / cities: Scottsdale, Arizona • Dublin, California • Riverside, California + 29 more

Conditions: Sickle Cell Disease, Sickle Cell Crisis
Interventions: Ketamine hydrochloride injection, Placebo; Drug · Other
Lead sponsor: Boston Children's Hospital; Other
Eligibility: 6 Years to 24 Years
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Brookline, Massachusetts

Conditions: Subcutaneous Fat
Interventions: CBL-514 Injection, 0.9% Sodium Chloride; Drug · Other
Lead sponsor: Caliway Biopharmaceuticals Co., Ltd.; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 107 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Pflugerville, Texas

Conditions: Evaluate Ketogenic Stress
Interventions: Exenatide/Exenatide extended release, Dapagliflozin, Placebo; Drug
Lead sponsor: University at Buffalo; Other
Eligibility: 18 Years to 65 Years
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 1
States / cities: Williamsville, New York

Conditions: Familial Chylomicronemia Syndrome
Interventions: Olezarsen, Placebo; Drug
Lead sponsor: Ionis Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 17
States / cities: Huntington Beach, California • San Francisco, California • Boca Raton, Florida + 13 more

Conditions: Hidradenitis Suppurativa (HS)
Interventions: Placebo, Adalimumab; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 206 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 9
States / cities: Beverly Hills, California • Encino, California • Irvine, California + 6 more

Conditions: Overweight, Obesity
Interventions: Semaglutide, Placebo (Semaglutide); Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: Not listed
Enrollment: 304 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 15
States / cities: Birmingham, Alabama • Los Angeles, California • Aurora, Colorado + 12 more

Conditions: Glabellar Lines
Interventions: Placebo, AGN-151586; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 638 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 18
States / cities: Birmingham, Alabama • Encino, California • Los Angeles, California + 15 more

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: Dupilumab SAR231893, Inhaled Corticosteroid, Inhaled Long-Acting Beta Agonist, Inhaled Long-Acting Muscarinic Antagonist, Placebo; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 939 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 51
States / cities: Andalusia, Alabama • Birmingham, Alabama • Dothan, Alabama + 46 more

Conditions: Hyperglycemia
Interventions: pasireotide; Drug
Lead sponsor: Robert R. Henry, MD; Other
Eligibility: 18 Years to 50 Years · Male only
Enrollment: 45 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: San Diego, California

Conditions: Painful Diabetic Neuropathies
Interventions: Low Dose: 16 mg Engensis (VM202), High Dose: 32 mg Engensis (VM202), Control- Placebo (normal saline); Biological · Other
Lead sponsor: Helixmith Co., Ltd.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 104 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 13
States / cities: Walnut Creek, California • Orlando, Florida • Palm Beach Gardens, Florida + 9 more

Conditions: Postoperative Pain, Spinal Fusion
Interventions: Local infiltration with 0.25% bupivacaine and epinephrine, Placebo of equal volume injectable saline; Procedure
Lead sponsor: Boston Children's Hospital; Other
Eligibility: 10 Years to 17 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Boston, Massachusetts

Search by objective public record fields.

A Study to Evaluate the Safety and Immunogenicity for Regimen Selection of Ad26.RSV.preF and/or RSV preF Protein Combinations Followed by Expanded Safety Evaluation in Adults Aged 60 Years and Older

A Study of the Effect of ZT-01 on Night-time Hypoglycemia in Type 1 Diabetes

Safety and Efficacy of Repeated Administrations of NurOwn® in ALS Patients

Efficacy and Safety of XG-102 in Reduction of Post-cataract Surgery Intraocular Inflammation and Pain

Placebo Controlled Trial of Botulinum Toxin for Gastroparesis

Phase 3 Study to Evaluate the Efficacy & Safety of Tralokinumab in Adults & Adolescents With OCS Dependent Asthma

Phase 1 Multicenter, Single Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Response of PE0139 Injection in Adult Subjects With Type 2 Diabetes Mellitus

18F-Dihydroxyphenylalanine (DOPA) Positron Emission Tomography (PET) Study to Explore Dopamine Synthesis Capacity in the Whole Striatum After 2 Weeks of Treatment With Ralmitaront or Placebo in Participants With Schizophrenia

A Phase 1/2 Study to Evaluate ALN-KHK in Overweight to Obese Healthy Volunteers and Obese Patients With T2DM

Erector Spinae Plane Block With Bupivacaine for Medical Thoracoscopy

Effect of ARC1779 on Cerebral Microembolism in Patients Undergoing Carotid Endarterectomy

A Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis

A Study to Evaluate the Safety and Immune Response of mRNA-1345, a Vaccine Targeting Respiratory Syncytial Virus (RSV), When Co-administered With a Fluzone HD, in Adults ≥65 Years of Age

Optimal Timing of Ketamine Initiation for SCD Pain

A Study to Evaluate the Efficacy, Safety and Tolerability of CBL-514 Injection for Reducing Abdominal Subcutaneous Fat

An Investigation Into the Effect of Dapagliflozin on Ketogenesis in Type 1 Diabetes

A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRx) Administered to Patients With Familial Chylomicronemia Syndrome (FCS)

Safety and Efficacy of Adalimumab (Humira) for Hidradenitis Suppurativa (HS) Peri-Surgically

Two-year Research Study Investigating How Well Semaglutide Works in People Suffering From Overweight or Obesity

A Study to Assess Adverse Events and Change in Disease Activity of Intramuscular AGN-151586 Injection in Adult Participants With Glabellar Lines

Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate-to-severe COPD With Type 2 Inflammation

Somatostatin Analogue SOM230 (Pasireotide) in Healthy Male Volunteers

Safety and Efficacy Study for the Treatment of Painful Diabetic Neuropathy

Postoperative Pain Control Using Local Wound Infiltration in Adolescent Idiopathic Surgery